Boyd Watterson Asset Management LLC OH Boosts Holdings in Johnson & Johnson (NYSE:JNJ)

Boyd Watterson Asset Management LLC OH lifted its stake in Johnson & Johnson (NYSE:JNJ) by 24.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 21,304 shares of the company’s stock after purchasing an additional 4,227 shares during the quarter. Johnson & Johnson accounts for approximately 1.1% of Boyd Watterson Asset Management LLC OH’s holdings, making the stock its 23rd biggest position. Boyd Watterson Asset Management LLC OH’s holdings in Johnson & Johnson were worth $3,533,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of JNJ. Norges Bank purchased a new position in shares of Johnson & Johnson in the 4th quarter worth about $4,390,037,000. GAMMA Investing LLC raised its position in shares of Johnson & Johnson by 24,450.4% in the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company’s stock worth $1,196,596,000 after purchasing an additional 7,185,977 shares during the last quarter. Bank of New York Mellon Corp raised its position in shares of Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock worth $3,844,580,000 after purchasing an additional 4,842,582 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Johnson & Johnson by 134.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company’s stock worth $1,149,536,000 after purchasing an additional 4,559,147 shares during the last quarter. Finally, Northern Trust Corp raised its position in shares of Johnson & Johnson by 12.3% in the 4th quarter. Northern Trust Corp now owns 30,813,175 shares of the company’s stock worth $4,456,201,000 after purchasing an additional 3,363,235 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Bank of America lifted their price target on Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Thursday, July 17th. UBS Group reissued a “buy” rating and issued a $190.00 target price (up previously from $180.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Barclays boosted their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Finally, Morgan Stanley boosted their target price on Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Eleven research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $172.87.

Johnson & Johnson Price Performance

NYSE JNJ opened at $167.90 on Wednesday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The firm has a market capitalization of $403.99 billion, a P/E ratio of 17.96, a PEG ratio of 2.09 and a beta of 0.41. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The company has a 50-day moving average price of $154.29 and a 200-day moving average price of $155.12.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 33.07%. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter in the prior year, the firm earned $2.82 EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 3.10%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson’s payout ratio is currently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.